The route to personalized medicine in bladder cancer: where do we stand?

Francesco Massari, Chiara Ciccarese, Matteo Santoni, Matteo Brunelli, Alessandro Conti, Alessandra Modena, Rodolfo Montironi, Daniele Santini, Liang Cheng, Guido Martignoni, Stefano Cascinu, Giampaolo Tortora

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Recent advances in molecular biology and drug design have described novel targets in bladder cancer. EGFR, fibroblast growth factor receptor (FGFR), VEGFR, phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, PD-1, cyclooxygenase 2 (COX-2), Aurora kinase A, and miRNA are just examples of these opening frontiers. In addition, epithelial to mesenchymal transition (EMT) and cancer stem cells (CSCs) are promising candidates for future therapeutic approaches. Novel agents, combination, and sequences are emerging from the 747 clinical studies presently in course in bladder cancer to optimize patient outcomes. This report describes the emerging targets and provides an update on ongoing phase I, II, and III trials and preliminary results on targeted agents, used alone, in sequences, or in combination for patients with bladder cancer.

Original languageEnglish
Pages (from-to)325-336
Number of pages12
JournalTargeted Oncology
Volume10
Issue number3
DOIs
StatePublished - Sep 5 2015

Fingerprint

Precision Medicine
Urinary Bladder Neoplasms
Aurora Kinase A
Vascular Endothelial Growth Factor Receptor-3
Fibroblast Growth Factor Receptors
Epithelial-Mesenchymal Transition
1-Phosphatidylinositol 4-Kinase
Neoplastic Stem Cells
Drug Design
Sirolimus
Cyclooxygenase 2
MicroRNAs
Mesenchymal Stromal Cells
Molecular Biology
Therapeutics

Keywords

  • Bladder cancer
  • Novel agents
  • Personalized medicine
  • Target agents

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Massari, F., Ciccarese, C., Santoni, M., Brunelli, M., Conti, A., Modena, A., ... Tortora, G. (2015). The route to personalized medicine in bladder cancer: where do we stand? Targeted Oncology, 10(3), 325-336. https://doi.org/10.1007/s11523-015-0357-x

The route to personalized medicine in bladder cancer : where do we stand? / Massari, Francesco; Ciccarese, Chiara; Santoni, Matteo; Brunelli, Matteo; Conti, Alessandro; Modena, Alessandra; Montironi, Rodolfo; Santini, Daniele; Cheng, Liang; Martignoni, Guido; Cascinu, Stefano; Tortora, Giampaolo.

In: Targeted Oncology, Vol. 10, No. 3, 05.09.2015, p. 325-336.

Research output: Contribution to journalArticle

Massari, F, Ciccarese, C, Santoni, M, Brunelli, M, Conti, A, Modena, A, Montironi, R, Santini, D, Cheng, L, Martignoni, G, Cascinu, S & Tortora, G 2015, 'The route to personalized medicine in bladder cancer: where do we stand?', Targeted Oncology, vol. 10, no. 3, pp. 325-336. https://doi.org/10.1007/s11523-015-0357-x
Massari F, Ciccarese C, Santoni M, Brunelli M, Conti A, Modena A et al. The route to personalized medicine in bladder cancer: where do we stand? Targeted Oncology. 2015 Sep 5;10(3):325-336. https://doi.org/10.1007/s11523-015-0357-x
Massari, Francesco ; Ciccarese, Chiara ; Santoni, Matteo ; Brunelli, Matteo ; Conti, Alessandro ; Modena, Alessandra ; Montironi, Rodolfo ; Santini, Daniele ; Cheng, Liang ; Martignoni, Guido ; Cascinu, Stefano ; Tortora, Giampaolo. / The route to personalized medicine in bladder cancer : where do we stand?. In: Targeted Oncology. 2015 ; Vol. 10, No. 3. pp. 325-336.
@article{cc79fbb784774e4b9ed4ce3a82bc8412,
title = "The route to personalized medicine in bladder cancer: where do we stand?",
abstract = "Recent advances in molecular biology and drug design have described novel targets in bladder cancer. EGFR, fibroblast growth factor receptor (FGFR), VEGFR, phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, PD-1, cyclooxygenase 2 (COX-2), Aurora kinase A, and miRNA are just examples of these opening frontiers. In addition, epithelial to mesenchymal transition (EMT) and cancer stem cells (CSCs) are promising candidates for future therapeutic approaches. Novel agents, combination, and sequences are emerging from the 747 clinical studies presently in course in bladder cancer to optimize patient outcomes. This report describes the emerging targets and provides an update on ongoing phase I, II, and III trials and preliminary results on targeted agents, used alone, in sequences, or in combination for patients with bladder cancer.",
keywords = "Bladder cancer, Novel agents, Personalized medicine, Target agents",
author = "Francesco Massari and Chiara Ciccarese and Matteo Santoni and Matteo Brunelli and Alessandro Conti and Alessandra Modena and Rodolfo Montironi and Daniele Santini and Liang Cheng and Guido Martignoni and Stefano Cascinu and Giampaolo Tortora",
year = "2015",
month = "9",
day = "5",
doi = "10.1007/s11523-015-0357-x",
language = "English",
volume = "10",
pages = "325--336",
journal = "Targeted Oncology",
issn = "1776-2596",
publisher = "Springer Paris",
number = "3",

}

TY - JOUR

T1 - The route to personalized medicine in bladder cancer

T2 - where do we stand?

AU - Massari, Francesco

AU - Ciccarese, Chiara

AU - Santoni, Matteo

AU - Brunelli, Matteo

AU - Conti, Alessandro

AU - Modena, Alessandra

AU - Montironi, Rodolfo

AU - Santini, Daniele

AU - Cheng, Liang

AU - Martignoni, Guido

AU - Cascinu, Stefano

AU - Tortora, Giampaolo

PY - 2015/9/5

Y1 - 2015/9/5

N2 - Recent advances in molecular biology and drug design have described novel targets in bladder cancer. EGFR, fibroblast growth factor receptor (FGFR), VEGFR, phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, PD-1, cyclooxygenase 2 (COX-2), Aurora kinase A, and miRNA are just examples of these opening frontiers. In addition, epithelial to mesenchymal transition (EMT) and cancer stem cells (CSCs) are promising candidates for future therapeutic approaches. Novel agents, combination, and sequences are emerging from the 747 clinical studies presently in course in bladder cancer to optimize patient outcomes. This report describes the emerging targets and provides an update on ongoing phase I, II, and III trials and preliminary results on targeted agents, used alone, in sequences, or in combination for patients with bladder cancer.

AB - Recent advances in molecular biology and drug design have described novel targets in bladder cancer. EGFR, fibroblast growth factor receptor (FGFR), VEGFR, phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, PD-1, cyclooxygenase 2 (COX-2), Aurora kinase A, and miRNA are just examples of these opening frontiers. In addition, epithelial to mesenchymal transition (EMT) and cancer stem cells (CSCs) are promising candidates for future therapeutic approaches. Novel agents, combination, and sequences are emerging from the 747 clinical studies presently in course in bladder cancer to optimize patient outcomes. This report describes the emerging targets and provides an update on ongoing phase I, II, and III trials and preliminary results on targeted agents, used alone, in sequences, or in combination for patients with bladder cancer.

KW - Bladder cancer

KW - Novel agents

KW - Personalized medicine

KW - Target agents

UR - http://www.scopus.com/inward/record.url?scp=84940899988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940899988&partnerID=8YFLogxK

U2 - 10.1007/s11523-015-0357-x

DO - 10.1007/s11523-015-0357-x

M3 - Article

C2 - 25634607

AN - SCOPUS:84940899988

VL - 10

SP - 325

EP - 336

JO - Targeted Oncology

JF - Targeted Oncology

SN - 1776-2596

IS - 3

ER -